This expert witness is a pharmacologist with more than 30 years of experience in pharmacology and pharmaceutical development, with a focus on regulatory affairs, clinical research, and the development of drugs, biologics, and medical devices. Their work includes evaluation of pharmacology, toxicology, and clinical data, as well as oversight of regulatory strategy and compliance for therapies addressing high-risk diseases. Educational background includes a Doctor of Philosophy in Pharmacology, supported by advanced training in biostatistics, pharmacokinetics, bioavailability, and clinical research methodologies.

Their experience spans regulatory and clinical functions central to pharmaceutical development, including adverse experience reporting requirements, IND and NDA submissions, clinical compliance with Good Clinical Practice standards, and data management for clinical studies. This includes coordination of regulatory submissions, clinical site audits, monitoring of study conduct, and implementation of quality assurance and compliance programs. Their work also involves preparation of policy guidance, evaluation of labeling and safety considerations, and development of regulatory strategies supporting product approval and lifecycle management.

Their background includes responsibility for regulatory program oversight, coordination of clinical and regulatory activities, and management of submissions and compliance functions across government and industry settings, including work associated with the Food and Drug Administration and the National Institutes of Health. Their consulting work also involves strategic planning and evaluation of clinical, pharmacology, and toxicology studies to support product development and regulatory decision-making. Their expert witness experience includes more than 5 years of involvement in matters related to pharmacology, regulatory compliance, and pharmaceutical development. Professional credentials include Regulatory Affairs Certification and completion of clinical research training through the National Institutes of Health. The expert has also been involved with organizations such as the Drug Information Association, the Regulatory Affairs Professionals Society, and the Association of Clinical Research Professionals, reflecting engagement in development and review of clinical and regulatory standards.